Talk:Gonadotropin-releasing hormone agonist

This is the talk page for discussing improvements to the Gonadotropin-releasing hormone agonist article.
This is not a forum for general discussion of the article's subject.

Put new text under old text. Click here to start a new topic.
New to Wikipedia? Welcome! Learn to edit; get help.

Article policies

Find medical sources: Source guidelines · PubMed · Cochrane · DOAJ · Gale · OpenMD · ScienceDirect · Springer · Trip · Wiley · TWL

Pharmacology Mid‑importance

	This article is within the scope of WikiProject Pharmacology, a collaborative effort to improve the coverage of Pharmacology on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.PharmacologyWikipedia:WikiProject PharmacologyTemplate:WikiProject Pharmacologypharmacology articles
Mid	This article has been rated as Mid-importance on the project's importance scale.

Medicine: Reproductive Mid‑importance

	Medicine portal This article is within the scope of WikiProject Medicine, which recommends that medicine-related articles follow the Manual of Style for medicine-related articles and that biomedical information in any article use high-quality medical sources. Please visit the project page for details or ask questions at Wikipedia talk:WikiProject Medicine.MedicineWikipedia:WikiProject MedicineTemplate:WikiProject Medicinemedicine articles
Mid	This article has been rated as Mid-importance on the project's importance scale.
	This article is supported by the Reproductive medicine task force (assessed as Mid-importance).

Women's Health Mid‑importance

	This article is within the scope of WikiProject Women's Health, a collaborative effort to improve the coverage of Women's Health on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.Women's HealthWikipedia:WikiProject Women's HealthTemplate:WikiProject Women's Healthwomen's health articles
Mid	This article has been rated as Mid-importance on the importance scale.

Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Gonadotropin-releasing hormone agonist.

PubMed provides review articles from the past five years (limit to free review articles)
The TRIP database provides clinical publications about evidence-based medicine.
Other potential sources include: Centre for Reviews and Dissemination and CDC

the most imp section is flare effect and down regulation[edit]

it explains the mechanism. we could expand on this section... —Preceding unsigned comment added by 68.61.150.75 (talk) 18:57, 27 December 2009 (UTC)[reply]

Control Aging[edit]

GnRH treatment represents a potential means of slowing the progress of aging or age-related diseases, the researchers say.

http://news.yahoo.com/brain-region-found-control-aging-191717771.html — Preceding unsigned comment added by 76.176.108.8 (talk) 05:11, 22 January 2014 (UTC)[reply]

Proposed deletion of specific drug links from External links section[edit]

The specific ones belong on the individual articles (unless any discuss the agents in general) - deleting those 5 would leave just 2. - Rod57 (talk) 16:34, 17 March 2016 (UTC)[reply]

External links modified[edit]

Hello fellow Wikipedians,

I have just modified 2 external links on Gonadotropin-releasing hormone agonist. Please take a moment to review my edit. If you have any questions, or need the bot to ignore the links, or the page altogether, please visit this simple FaQ for additional information. I made the following changes:

When you have finished reviewing my changes, you may follow the instructions on the template below to fix any issues with the URLs.

This message was posted before February 2018. After February 2018, "External links modified" talk page sections are no longer generated or monitored by InternetArchiveBot. No special action is required regarding these talk page notices, other than regular verification using the archive tool instructions below. Editors have permission to delete these "External links modified" talk page sections if they want to de-clutter talk pages, but see the RfC before doing mass systematic removals. This message is updated dynamically through the template {{source check}} (last update: 18 January 2022).

If you have discovered URLs which were erroneously considered dead by the bot, you can report them with this tool.
If you found an error with any archives or the URLs themselves, you can fix them with this tool.

Cheers.—InternetArchiveBot (Report bug) 16:49, 16 January 2018 (UTC)[reply]

Penile atrophy[edit]

I heard Dr. William Powers talk about it during his presentations, as well as some anecdotal evidence. But I've been unable to find any other academic sources. Has anyone found any?

Masslan (talk) 18:34, 5 May 2021 (UTC)[reply]

Expense[edit]

This is bad economics:

GnRH analogues are available as generic medications. Despite this, they continue to be very expensive.

The problem here is that it simply assumes that R&D cost dominates in the case of every medication, and production and distribution are never a primary cost driver.

But quite possibly some drugs are indeed hard to synthesize, or don't have a large usage base to amortize the facilities cost, or are not entirely shelf stable, requiring complex just-in-time manufacture, to pluck a few possibilities out of thin air rather effortlessly.

If there was no cost drop at all between proprietary and generic, then maybe there's some smoke here. — MaxEnt 03:38, 2 November 2021 (UTC)[reply]

Rationale for puberty blockers[edit]

@Snokalok Taylor et al (2024) says:

Rationales for puberty suppression in the Dutch treatment protocol, which has informed practice internationally, were to alleviate worsening gender dysphoria, allow time for gender exploration, and pause development of secondary sex characteristics to make passing in the desired gender role easier. Practice guidelines propose other indications for puberty suppression, including allowing time and/or capacity for decision-making about masculinising or feminising hormone interventions, and improving quality of life.

This is a recent systematic review and it states that there are multiple reasons for blockers, beyond the straightforward "time to think", and cites the originating Dutch Protocol in support. This is not a new perspective - it is the original perspective, restated in a recent, high quality MEDRS.

This is a complex and highly controversial area with disagreement between MEDRS. I don't think an unsourced claim in wikivoice that it is simply about "pending treatment decisions" does justice to this, and I would suggest keeping references here as blandly factual and neutral as possible and confining the disagreement between MEDRS to the main page. Void if removed (talk) 20:21, 3 May 2024 (UTC)[reply]

Then how bout "for a variety of reasons". Saying nothing at all risks them being confused with testosterone blockers like cyproacetate Snokalok (talk) 11:17, 4 May 2024 (UTC)[reply]

How about "to delay development of secondary sex characteristics"? I think all reasons agree that's why, but leaves out the more varied why of the why of it (improve mental health/time to think/better "passing" in adulthood). Void if removed (talk) 12:44, 4 May 2024 (UTC)[reply]

Reasonable, I'll take that deal. Snokalok (talk) 13:41, 4 May 2024 (UTC)[reply]